Flutamide (Eulexin) - Comprehensive Research Paper

Document Information

• Created: 2025-12-26
• Purpose: Clinical reference for hormone therapy product knowledge
• Paper Number: 56 of 76 (Anti-Androgens: Nonsteroidal - First Generation)

1. Summary

Flutamide is a first-generation nonsteroidal antiandrogen (NSAA) marketed under the brand name Eulexin, FDA-approved in 1989 for the treatment of metastatic prostate cancer in combination with LHRH agonists. As the first NSAA approved for prostate cancer in the United States, flutamide represented a significant advance in combined androgen blockade therapy. However, its clinical utility has been severely limited by a black box warning for potentially fatal hepatotoxicity.

The medication competitively inhibits androgen receptor binding, blocking testosterone and dihydrotestosterone effects at target tissues. Unlike bicalutamide, flutamide has a short half-life of approximately 6 hours, requiring three-times-daily dosing to maintain therapeutic levels. The medication is extensively metabolized by hepatic cytochrome P450 enzymes (primarily CYP3A4 and CYP1A2) to its active metabolite, 2-hydroxyflutamide.

Flutamide carries an FDA black box warning due to numerous cases of severe cholestatic hepatitis, hepatic failure, and death. By 1996, 46 cases of severe cholestatic hepatitis with 20 fatalities had been reported. A 2021 literature review identified 15 cases of serious hepatotoxicity in women treated with flutamide, including 7 liver transplants and 2 deaths. The hepatotoxicity is attributed to mitochondrial toxicity from the hydroxyflutamide metabolite.

Due to these serious safety concerns, flutamide is no longer recommended as first-line therapy for prostate cancer, having been largely replaced by bicalutamide and newer second-generation agents (enzalutamide, apalutamide, darolutamide). Off-label use for conditions such as hirsutism, PCOS, and acne is controversial and discouraged by most clinical guidelines given the hepatotoxicity risk.

Goal Relevance:

• Managing prostate cancer symptoms and progression
• Seeking alternatives for prostate cancer treatment when other medications are not suitable
• Addressing hormonal imbalances related to androgen activity
• Exploring options for combined androgen blockade in prostate cancer
• Understanding risks and benefits of antiandrogen therapy for prostate cancer
• Investigating historical treatments for conditions like hirsutism or PCOS (not recommended due to safety concerns)

2. Mechanism of Action

Primary Mechanism: Androgen Receptor Antagonism

Flutamide acts as a selective, competitive, silent antagonist of the androgen receptor (AR). The medication and its active metabolite 2-hydroxyflutamide bind to the ligand-binding domain of the AR, preventing testosterone and dihydrotestosterone from activating receptor-mediated gene transcription.

Molecular Mechanism:

• Competitive binding to cytosolic androgen receptors
• Prevents androgen-induced conformational change
• Blocks nuclear translocation of androgen-receptor complex
• Inhibits DNA binding and transcription activation

Active Metabolite: 2-Hydroxyflutamide

Flutamide is extensively metabolized to 2-hydroxyflutamide, which is the primary active species:

• Higher AR binding affinity than parent compound
• Responsible for majority of antiandrogen activity
• Also implicated in hepatotoxicity mechanism

Structural Classification

Flutamide is a monoarylpropionamide derivative:

• Chemical class: Anilide
• Related compounds: Bicalutamide (diarylpropionamide), nilutamide (hydantoin)
• First-generation NSAA alongside nilutamide and bicalutamide

Pure Antiandrogen Properties

Like other NSAAs, flutamide is a "pure" antiandrogen:

• No progestogenic activity
• No glucocorticoid activity
• No mineralocorticoid activity
• Does not suppress gonadotropin secretion directly

Peripheral Blockade Consequences

When AR blockade occurs peripherally:

• Hypothalamic feedback is disrupted
• Increased LH and FSH secretion
• Elevated serum testosterone levels
• Increased estrogen via peripheral aromatization
• Results in gynecomastia when used as monotherapy

Additional Receptor Activity

Aryl Hydrocarbon Receptor (AhR) Agonism:

• Flutamide has been identified as an AhR agonist
• This activity may contribute to hepatotoxicity
• AhR activation can induce hepatic cytochrome P450 enzymes
• May explain the unique hepatotoxicity profile of flutamide

3. FDA-Approved Indications

Approved Indications

Stage B2-C Prostatic Carcinoma:

• Locally confined prostate cancer with high risk features
• Used in combination with LHRH agonist
• Part of combined androgen blockade (CAB)

Stage D2 Metastatic Carcinoma of the Prostate:

• Metastatic prostate cancer
• Used in combination with LHRH agonist (leuprolide, goserelin)
• Initial approval indication (1989)

FDA Approval Timeline

Off-Label Uses (Controversial)

The following uses are NOT FDA-approved and carry significant hepatotoxicity risk:

• Hirsutism - Historical off-label use, now discouraged
• Polycystic Ovary Syndrome (PCOS) - Not recommended by ACOG
• Female pattern hair loss - Not recommended due to risk profile
• Acne - Rarely used given alternatives available

Important Warning: Off-label use is NOT recommended due to potentially fatal hepatotoxicity. Safer alternatives exist for all off-label indications.

4. Dosing and Administration

FDA-Approved Dosing (Prostate Cancer)

Standard Dose:

• 250 mg orally three times daily (750 mg total daily)
• Given in combination with LHRH agonist
• Treatment initiated at same time as LHRH agonist or slightly before to prevent "flare"

Administration:

• May be taken with or without food
• Capsules should be swallowed whole
• Consistent timing every 8 hours

Off-Label Dosing (Historical - Not Recommended)

Hirsutism/PCOS (Historical):

• Doses ranged from 62.5 mg to 500 mg daily
• 250 mg daily was common in studies
• Low-dose protocols (~1 mg/kg daily, ~62.5-125 mg) explored to reduce hepatotoxicity risk
• Current recommendation: Do not use flutamide for these indications

Dosing Considerations

Short Half-Life:

• Half-life approximately 6 hours
• Requires three-times-daily dosing for adequate serum levels
• Missed doses should be taken as soon as remembered
• If near next dose time, skip missed dose

No Dose Adjustment Typically Indicated For:

• Renal impairment (eliminated primarily hepatically)
• Age alone

Contraindicated For:

• Hepatic impairment (any degree)
• Elevated baseline transaminases

Treatment Duration

Prostate Cancer:

• Continue until disease progression
• Indefinite treatment in responding patients
• Discontinue immediately if liver injury develops

5. Pharmacokinetics

Absorption

• Bioavailability: Rapidly and completely absorbed orally
• Time to Peak (Tmax): ~2 hours (flutamide), ~2.5 hours (2-hydroxyflutamide)
• Food Effect: Food delays absorption but does not significantly affect overall exposure
• Steady State: Achieved within 24-48 hours due to short half-life

Distribution

• Protein Binding: 94-96% (both flutamide and metabolite)
• Primary Binding Proteins: Albumin
• Volume of Distribution: Moderate tissue distribution
• Active Metabolite: 2-hydroxyflutamide achieves higher concentrations than parent

Metabolism

Extensive Hepatic Metabolism:

• Primary Enzymes: CYP1A2, CYP3A4
• Primary Metabolite: 2-hydroxyflutamide (active, major metabolite)
• Mechanism of Hepatotoxicity: Hydroxyflutamide causes mitochondrial toxicity
  • Inhibits electron transport chain enzymes
  • Leads to hepatocyte death
  • Results in cholestatic hepatitis

Elimination

Short Half-Life:

• Flutamide: ~6 hours
• 2-hydroxyflutamide: ~6-8 hours

Excretion:

• Primarily renal (as metabolites)
• <1% excreted unchanged in urine
• Fecal excretion: ~4%

Pharmacokinetic Comparison

Clinical Implications

• Short half-life requires strict TID dosing
• Missed doses more problematic than with bicalutamide
• Drug interactions with CYP1A2/3A4 modulators clinically significant
• Hepatic metabolism makes liver function critical

6. Side Effects and Adverse Reactions

Black Box Warning: Hepatotoxicity

FDA Black Box Warning: Flutamide carries the most severe FDA warning due to potentially fatal hepatotoxicity:

• Hospitalization and death due to liver failure reported
• Cholestatic hepatitis is the primary mechanism
• Evidence includes elevated transaminases, jaundice, hepatic encephalopathy
• Death related to acute hepatic failure documented

Hepatotoxicity Statistics:

• By 1996: 46 cases of severe cholestatic hepatitis, 20 fatalities
• 2021 literature review: 15 cases serious hepatotoxicity in women, 7 liver transplants, 2 deaths
• More than 20 cases of fatal hepatic failure described overall
• Onset typically within first 3 months of treatment

Mechanism of Hepatotoxicity:

• Mitochondrial toxicity from 2-hydroxyflutamide metabolite
• Inhibition of electron transport chain enzymes in hepatocytes
• Results in hepatocellular necrosis and cholestasis
• Aryl hydrocarbon receptor activation may contribute

Common Side Effects

Gastrointestinal:

• Diarrhea (most common, up to 12%)
• Nausea
• Vomiting
• Anorexia

Endocrine (with monotherapy or combined therapy):

• Gynecomastia (9%)
• Hot flashes (61% when used with LHRH agonist)
• Impotence (33%)
• Decreased libido

General:

• Edema
• Fatigue
• Weakness

Serious Adverse Reactions

Hepatic:

• Transaminase elevations (common, often asymptomatic)
• Cholestatic jaundice
• Hepatic necrosis
• Fulminant hepatic failure
• Death

Cardiovascular:

• QT prolongation (rare)
• Cardiovascular events (in prostate cancer population)

Hematologic:

• Methemoglobinemia (rare but reported)
• Hemolytic anemia (rare)
• Sulfhemoglobinemia

Dermatologic:

• Rash
• Photosensitivity

Side Effect Comparison with Other First-Generation NSAAs

7. Drug Interactions

Cytochrome P450 Interactions

CYP1A2 and CYP3A4 Substrates: Flutamide is metabolized by both CYP1A2 and CYP3A4, creating potential for significant interactions.

CYP1A2 Inhibitors (increase flutamide/metabolite levels):

• Ciprofloxacin
• Fluvoxamine
• Cimetidine
• Smoking cessation (tobacco induces CYP1A2)

CYP3A4 Inhibitors (increase levels):

• Ketoconazole
• Itraconazole
• Clarithromycin
• Ritonavir
• Grapefruit juice

CYP Inducers (decrease levels):

• Rifampin
• Phenytoin
• Carbamazepine
• Phenobarbital
• St. John's Wort

Critical Interactions

Warfarin (Major):

• Flutamide may increase anticoagulant effect
• Increased INR and bleeding risk
• Close PT/INR monitoring required
• Dose adjustment of warfarin often necessary

Hepatotoxic Drugs (Avoid Combination):

• Acetaminophen (especially in excess)
• Statins
• Azole antifungals
• Methotrexate
• Other hepatotoxic medications
• Black box warning emphasizes avoiding concomitant hepatotoxic drugs

Drugs Affecting QT Interval

Though uncommon, flutamide has been associated with QT effects:

• Use caution with Class IA/III antiarrhythmics
• Avoid combination with other QT-prolonging drugs when possible

Drug-Food Interactions

• Food: Delays absorption but does not affect total exposure
• Grapefruit juice: May increase levels (CYP3A4 inhibition)
• Alcohol: No specific interaction, but avoid in liver disease

Drug-Lab Interactions

• May affect PSA measurements (therapeutic effect)
• May affect liver function tests (adverse effect)
• May cause false elevation of some laboratory values

8. Contraindications

Absolute Contraindications

Hypersensitivity:

• Known hypersensitivity to flutamide or any component
• History of severe reaction to flutamide

Severe Hepatic Impairment:

• Pre-existing severe liver disease
• Active hepatitis (any cause)
• Elevated baseline transaminases (ALT >2x ULN)

Pregnancy:

• Category D (prostate cancer - male only indication)
• Causes feminization of male fetus in animal studies
• Absolutely contraindicated in pregnant women

Use in Women (General):

• FDA-approved only for prostate cancer (males only)
• Off-label use strongly discouraged due to hepatotoxicity
• If used off-label, requires extensive counseling and monitoring

Relative Contraindications

Mild-Moderate Hepatic Impairment:

• Significantly increased risk of severe hepatotoxicity
• Generally should be avoided
• If used, requires extremely close monitoring

Concurrent Hepatotoxic Medications:

• Black box warning specifically cautions against combination
• Includes acetaminophen, statins, azole antifungals

CYP1A2/CYP3A4 Drug Interactions:

• Medications that inhibit metabolism may increase toxicity risk

Warnings and Precautions

Mandatory Liver Monitoring:

• Baseline LFTs required before initiation
• LFTs should be checked at least monthly for first 4 months
• More frequent monitoring if any risk factors
• Discontinue immediately if ALT >2x ULN or jaundice develops

Patient Counseling Required:

• Symptoms of liver injury (jaundice, dark urine, fatigue)
• Immediate discontinuation and medical attention if symptoms occur
• Importance of compliance with monitoring

9. Special Populations

Geriatric Patients

Primary Patient Population:

• Prostate cancer indication means elderly men are primary users
• Hepatotoxicity risk may be higher with age
• Comorbidities may increase interaction risk

Considerations:

• More frequent LFT monitoring recommended
• Assess polypharmacy for hepatotoxic drug combinations
• Consider alternatives (bicalutamide) with better safety profile

Pediatric Patients

Not Indicated:

• No approved pediatric indications
• Safety and efficacy not established
• Should not be used in children

Women

Off-Label Use Concerns:

Historical use in women for hirsutism/PCOS is strongly discouraged:

• 2021 review: 15 cases serious hepatotoxicity in women
• 7 liver transplants, 2 deaths documented
• Risk-benefit ratio unfavorable given available alternatives

ACOG Position:

• Does not recommend flutamide for PCOS-related hirsutism
• Safer alternatives available (spironolactone, oral contraceptives)

If Ever Used in Women (Not Recommended):

• Pregnancy must be excluded
• Effective contraception mandatory
• Monthly LFT monitoring minimum
• Lowest effective dose
• Patient counseling about hepatotoxicity signs

Hepatic Impairment

Strict Contraindication:

• Any degree of hepatic impairment increases risk dramatically
• Pre-existing liver disease: Contraindicated
• Elevated baseline ALT/AST: Do not initiate
• Avoid completely in patients with liver disease

Renal Impairment

• Primary elimination is hepatic (as metabolites)
• No dose adjustment typically required for renal impairment
• Limited data in severe renal impairment
• Use caution in end-stage renal disease

Patients with Multiple Risk Factors

Avoid flutamide if patient has:

• Baseline liver function abnormalities
• History of drug-induced liver injury
• Concurrent hepatotoxic medications
• Alcohol use disorder
• Viral hepatitis
• Non-alcoholic fatty liver disease

10. Monitoring Parameters

Pre-Treatment Assessment (Critical)

Mandatory:

• Liver function tests (ALT, AST, alkaline phosphatase, bilirubin)
• Complete blood count
• Serum creatinine

For Prostate Cancer:

• PSA baseline
• Disease staging

Patient Education:

• Signs/symptoms of hepatotoxicity
• Importance of monitoring compliance
• Written instructions about when to seek care

Hepatic Monitoring Protocol (Black Box Warning Requirements)

FDA-Mandated Schedule:

1. Baseline LFTs before initiation
2. Monthly LFTs for first 4 months minimum
3. Periodic LFTs thereafter

More Intensive Monitoring if:

• Any baseline abnormalities
• Concurrent hepatotoxic medications
• History of liver disease
• Symptoms suggestive of hepatic injury

Action Thresholds (Critical)

Discontinue Therapy If:

• ALT rises above 2x upper limit of normal (ULN)
• AST rises above 2x ULN
• Jaundice develops
• Any symptoms of hepatic dysfunction

Symptoms Requiring Immediate Discontinuation and Evaluation:

• Jaundice (yellowing of skin/eyes)
• Dark urine
• Right upper quadrant pain/tenderness
• Unexplained fatigue
• Nausea/anorexia
• Flu-like symptoms with elevated LFTs

Prostate Cancer Monitoring

Disease Response:

• PSA levels per oncology protocol
• Imaging as indicated
• Assessment for disease progression

Side Effect Assessment:

• Hot flash severity
• Sexual function
• Gynecomastia development
• Quality of life

Laboratory Monitoring Summary

Patient Self-Monitoring

Patients should report immediately:

• Yellowing of skin or eyes
• Dark-colored urine
• Light-colored stools
• Abdominal pain (especially right upper quadrant)
• Unusual fatigue or weakness
• Loss of appetite
• Nausea or vomiting

11. Cost and Availability

Brand and Generic Availability

Brand Name:

• Eulexin (Schering-Plough) - original brand, now discontinued in many markets

Generic Availability:

• Generic flutamide available since 2001
• Multiple generic manufacturers
• Brand Eulexin largely replaced by generics

Typical Pricing (United States, 2024)

Generic Flutamide 125 mg (180 capsules/month for TID dosing):

• Retail: $100-300
• With discount programs: $50-150
• Price varies significantly by pharmacy

Note on Prescribing:

• Due to hepatotoxicity concerns, many oncologists prefer bicalutamide
• Generic bicalutamide often similar or lower cost with better safety
• Insurance may require step therapy or prior authorization

Insurance Coverage

Commercial Insurance:

• Generally covered for prostate cancer with prior authorization
• May face step therapy requirements (try bicalutamide first)
• Off-label uses rarely covered

Medicare Part D:

• Covered for prostate cancer indication
• Generic tier placement
• Prior authorization common

Medicaid:

• Variable state-by-state coverage
• Generic preferred

International Availability

• Available globally as generic
• Brand Eulexin discontinued in many countries
• Lower cost internationally than in US
• Increasingly replaced by bicalutamide worldwide

Prescribing Trends

Due to black box warning and availability of safer alternatives:

• Prescribing has declined significantly since 1990s
• Most oncologists now prefer bicalutamide
• Flutamide use essentially limited to:
  • Patient intolerance to bicalutamide
  • Specific clinical scenarios
  • Cost-driven decisions (rare)

12. Clinical Evidence Summary

Pivotal Prostate Cancer Trials

Combined Androgen Blockade (CAB) Studies:

Flutamide was evaluated in combination with LHRH agonists:

• Demonstrated PSA response rates of 70-85%
• Combined therapy superior to LHRH agonist alone
• Marginal overall survival benefit in meta-analyses (~3-5% at 5 years)

NCI Intergroup Study (INT-0036):

• Landmark trial comparing leuprolide + flutamide vs. leuprolide + placebo
• Showed survival advantage for combined therapy
• Led to widespread adoption of CAB

Comparison with Other Antiandrogens

Flutamide vs. Bicalutamide:

• Similar efficacy in PSA response
• Bicalutamide has significantly better tolerability
• Bicalutamide has lower hepatotoxicity risk
• Bicalutamide allows once-daily dosing
• Bicalutamide now preferred first-line

Flutamide vs. Nilutamide:

• Similar efficacy
• Different toxicity profiles
• Nilutamide: visual disturbance, alcohol intolerance, interstitial pneumonitis
• Flutamide: hepatotoxicity, diarrhea

Hepatotoxicity Evidence

Case Series and Reports:

• By 1996: 46 documented cases of severe hepatitis, 20 deaths
• 2021 review in women: 15 serious cases, 7 transplants, 2 deaths
• Continued reports despite declining use
• Risk persists even at lower doses

Risk Factors Identified:

• Pre-existing liver disease
• Concurrent hepatotoxic medications
• Possibly higher risk in women
• Most cases occur within first 3 months

Hirsutism/PCOS Evidence (Historical)

Efficacy Studies:

• Multiple RCTs showed efficacy at 250-750 mg daily
• Lower doses (125-250 mg) also effective
• Low-dose protocols (~1 mg/kg) explored to reduce hepatotoxicity

Safety Studies:

• One study of 214 women on low-dose showed no hepatotoxicity
• However, serious cases still reported at low doses
• Risk-benefit unfavorable - not recommended for this use

13. Comparison with Alternatives

First-Generation NSAA Comparison

Why Bicalutamide is Preferred

1. Safety: Significantly lower hepatotoxicity risk
2. Convenience: Once-daily dosing vs. TID
3. Tolerability: Less GI toxicity (no diarrhea)
4. Cost: Generic pricing similar or better
5. Evidence: Extensive safety/efficacy data

Second-Generation Antiandrogens

Enzalutamide, Apalutamide, Darolutamide:

• More potent AR antagonism
• Additional mechanisms of action
• FDA-approved for CRPC
• Very different cost structure (expensive)
• Reserved for castration-resistant disease

Alternatives for Hirsutism/PCOS (Preferred)

For conditions where flutamide was historically used off-label:

14. Storage and Handling

Storage Requirements

Temperature:

• Store at controlled room temperature: 20-25°C (68-77°F)
• Excursions permitted: 15-30°C (59-86°F)

Environment:

• Protect from moisture
• Keep in original container
• Tight container closure

Light:

• Protect from excessive light exposure
• Store in opaque container

Handling Precautions

Healthcare Workers:

• Standard oral medication handling
• Not classified as hazardous by NIOSH
• Gloves recommended for routine handling

Pregnancy Exposure:

• Women who are or may become pregnant should avoid handling
• Causes feminization of male fetus in animal studies
• If handling required, use gloves
• Avoid handling broken/crushed capsules

Dispensing Considerations

Packaging:

• Available in bottles of 100, 180, 500 capsules
• 125 mg capsules standard strength

Capsule Integrity:

• Capsules should be swallowed whole
• Do not open, crush, or chew capsules
• If unable to swallow capsules, consult pharmacist

Stability

Shelf Life:

• Typically 2-3 years from manufacture
• Check expiration date on packaging

After Opening:

• Use within expiration date
• No special requirements after opening
• Maintain tight closure

15. References

Primary Literature

1. FDA Prescribing Information. Eulexin (flutamide) capsules. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. Flutamide. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf. Available at: https://www.ncbi.nlm.nih.gov/books/NBK548908/

3. Flutamide. StatPearls. NCBI Bookshelf. 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK482215/

4. Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer. PubMed. 2004.

Hepatotoxicity Case Reports

5. Fatal liver complications with flutamide. The Lancet. 2006.

6. Flutamide Induced Liver Injury in Female Patients. European Journal of Medical and Health Sciences. 2021.

7. The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. PubMed. 2008.

Clinical Guidelines

8. American College of Obstetricians and Gynecologists (ACOG). Clinical Practice Guidelines for Polycystic Ovary Syndrome.

9. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Prostate Cancer. 2024.

Comparative Studies

10. Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens. PMC. 2018.

11. Low-dose flutamide for hirsutism: into the limelight, at last. Nature Reviews Endocrinology. 2010.

Hirsutism Literature

12. Flutamide: Hirsutism in Women. PMC. 2014. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4062730/

Additional Resources

13. Drugs.com. Flutamide Monograph for Professionals. Available at: https://www.drugs.com/monograph/flutamide.html

14. Medscape. Flutamide dosing, indications, interactions, adverse effects. Available at: https://reference.medscape.com/drug/flutamide-342223

15. Wikipedia. Flutamide. Available at: https://en.wikipedia.org/wiki/Flutamide

16. Goal Archetype Integration

Primary Archetype: Anti-Androgen Therapy

Flutamide serves as a pure antiandrogen agent, making it relevant for specific therapeutic archetypes:

Prostate Cancer Management (Primary Archetype)

• Goal: Block androgen receptor activation in prostate tumor cells
• Mechanism Alignment: Competitive AR antagonism prevents testosterone/DHT-driven tumor growth
• Combined Androgen Blockade (CAB): Synergizes with LHRH agonists for complete androgen suppression
• Therapeutic Window: Designed for advanced/metastatic disease where benefits outweigh hepatotoxicity risk

Androgen Suppression Goals:

Archetype Contraindications

NOT Appropriate for These Archetypes:

• Wellness optimization - No role; hepatotoxicity risk unacceptable
• Cosmetic antiandrogen therapy - Safer alternatives exist (spironolactone)
• Transgender feminizing hormone therapy - Bicalutamide or spironolactone preferred
• Athletic/bodybuilding recovery - No legitimate use case
• Anti-aging protocols - No benefit; significant risk

Patient Goal Alignment Questions

Before prescribing, verify alignment:

1. Is this a life-threatening condition (metastatic prostate cancer)?
2. Have safer alternatives been exhausted or contraindicated?
3. Can the patient commit to mandatory LFT monitoring?
4. Does the patient understand the BLACK BOX hepatotoxicity warning?
5. Is the patient willing to immediately discontinue if symptoms develop?

17. Age-Stratified Dosing

Overview

Flutamide dosing is NOT age-adjusted by FDA labeling, but clinical considerations vary significantly by age group due to hepatotoxicity risk and comorbidities.

Adult Men (18-64 Years)

Prostate Cancer (Standard Dosing):

• Dose: 250 mg orally three times daily (750 mg total)
• Schedule: Every 8 hours for consistent serum levels
• Duration: Until disease progression or intolerable toxicity
• With: LHRH agonist (leuprolide, goserelin, etc.)

Younger Patients (18-50) - Special Considerations:

• Prostate cancer rare in this age group
• If used, standard dosing applies
• May have better hepatic reserve but still requires monitoring
• Consider fertility implications of CAB therapy

Geriatric Patients (65+ Years)

Primary Use Population: Prostate cancer predominantly affects older men; most flutamide users are 65+.

Dosing Considerations:

*No dose reduction per FDA, but clinical judgment favors alternatives in very elderly.

Age-Related Hepatotoxicity Risk Factors:

• Decreased hepatic blood flow
• Reduced cytochrome P450 activity
• Increased prevalence of fatty liver disease
• Higher likelihood of hepatotoxic comedications
• Delayed recognition of hepatic symptoms

Pediatric Patients

Not Indicated:

• No FDA-approved pediatric indications
• Safety and efficacy not established in children
• Theoretical concern for bone development effects
• Do not prescribe to patients under 18

Women (Historical Off-Label - NOT RECOMMENDED)

• 2021 literature review: 15 serious hepatotoxicity cases
• 7 liver transplants documented
• 2 deaths documented
• Risk far outweighs benefit for cosmetic indications

Historical Off-Label Dosing (Reference Only):

Preferred Alternatives for Women:

• Spironolactone 50-200 mg daily
• Oral contraceptives (estrogen-progestin)
• Bicalutamide 25-50 mg daily (if NSAA needed)
• Eflornithine topical (for facial hirsutism)

Dose Adjustments

Renal Impairment:

• No dose adjustment required
• Flutamide metabolites renally excreted but parent drug hepatically cleared
• CrCl < 30: Limited data, use with caution

Hepatic Impairment:

• Contraindicated in ANY degree of hepatic impairment
• Do not initiate if baseline ALT/AST > 2x ULN
• No safe dose in liver disease

18. Drug Interactions - BLACK BOX Hepatotoxicity Focus

Flutamide is associated with severe hepatotoxicity. By 1996, 46 cases of severe hepatitis with 20 fatalities were documented. Hospitalization and death have occurred. Patients must have baseline and monthly liver function tests.

Critical Drug-Drug Interactions

Category 1: AVOID - Hepatotoxic Combinations

Absolute Contraindications (Hepatotoxic Synergy):

Moderately Hepatotoxic Combinations (Use with Extreme Caution):

• Amiodarone
• Sulfasalazine
• Nitrofurantoin
• Tetracyclines (especially minocycline)
• Anabolic steroids
• Herbal supplements (kava, comfrey, germander)

Category 2: Pharmacokinetic Interactions

CYP1A2 Inhibitors (Increase Flutamide/Hydroxyflutamide Levels):

CYP3A4 Inhibitors (Increase Levels):

CYP Inducers (Decrease Levels - May Reduce Efficacy):

Category 3: Pharmacodynamic Interactions

Warfarin - MAJOR Interaction:

• Flutamide increases anticoagulant effect
• Mechanism: Protein binding displacement + possible CYP inhibition
• Management: Monitor INR closely; anticipate warfarin dose reduction
• Frequency: Check INR within 3-5 days of flutamide initiation, then weekly x 4

QT-Prolonging Drugs:

• Flutamide has minor QT effects; use caution with:
  • Class IA antiarrhythmics (quinidine, procainamide)
  • Class III antiarrhythmics (amiodarone, sotalol)
  • Fluoroquinolones
  • Macrolides (erythromycin, clarithromycin)
  • Antipsychotics (haloperidol, ziprasidone)

Alcohol Interaction

Alcohol and Flutamide:

• No direct pharmacokinetic interaction
• HOWEVER: Alcohol consumption increases baseline hepatotoxicity risk
• Recommendation: Abstain from alcohol during flutamide therapy
• Chronic alcohol use is a relative contraindication

Supplement and Herbal Interactions

AVOID - Hepatotoxic Herbs/Supplements:

19. Bloodwork Impact - LFTs Critical

Mandatory Monitoring Protocol

FDA Black Box Requires:

1. Baseline LFTs - Do not initiate without normal baseline
2. Monthly LFTs - Minimum first 4 months
3. Periodic LFTs - Ongoing during therapy
4. Immediate LFTs - If any symptoms develop

Liver Function Test Panel

Required Tests and Thresholds:

Monitoring Schedule by Risk Category

Standard Risk (No Risk Factors):

High Risk (Any Risk Factor Present):

Risk Factors Requiring Enhanced Monitoring:

• Age > 75 years
• Concurrent hepatotoxic medications
• History of any liver disease
• Alcohol use (any amount)
• Baseline ALT/AST 1-2x ULN (borderline - consider not initiating)
• Diabetes or metabolic syndrome
• Obesity (NAFLD risk)

Interpreting Results - Decision Algorithm

BASELINE LFTs:
├── ALT/AST > 2x ULN → DO NOT INITIATE
├── ALT/AST 1.5-2x ULN → AVOID; if essential, weekly monitoring
└── ALT/AST < 1.5x ULN → May initiate with monthly monitoring

ON-TREATMENT LFT ELEVATION:
├── ALT/AST > 3x ULN → DISCONTINUE IMMEDIATELY
├── ALT/AST 2-3x ULN → DISCONTINUE; evaluate for hepatitis
├── ALT/AST 1.5-2x ULN → Recheck in 1 week; hold if rising
└── ALT/AST 1-1.5x ULN → Recheck in 2 weeks; continue if stable

ANY BILIRUBIN ELEVATION:
└── Evaluate for cholestasis; likely discontinue

SYMPTOMS (regardless of LFT level):
├── Jaundice → DISCONTINUE IMMEDIATELY
├── Dark urine → DISCONTINUE IMMEDIATELY
├── RUQ pain → DISCONTINUE; urgent evaluation
├── Unexplained fatigue → Check LFTs within 24-48 hours
└── Nausea/anorexia → Check LFTs within 24-48 hours

Expected Bloodwork Changes (Non-Hepatic)

Endocrine Effects (When Used as Monotherapy or Before LHRH Agonist):

Prostate Cancer Markers:

Potential Hematologic Effects (Rare):

Post-Discontinuation Monitoring

If Discontinued for Hepatotoxicity:

1. Check LFTs within 1 week of discontinuation
2. Weekly LFTs until normalization
3. Hepatology referral if:
   • Bilirubin > 2x ULN
   • ALT/AST > 5x ULN
   • INR prolongation
   • Encephalopathy symptoms

Recovery Timeline:

• Most cases resolve within 2-3 months
• Severe cases may require 6+ months
• Permanent liver damage possible
• Transplant may be required in severe cases

20. Protocol Integration

Combined Androgen Blockade (CAB) Protocol

Standard Protocol - Metastatic Prostate Cancer:

Initiation (Prevent Testosterone Flare):

1. Day 1: Start flutamide 250 mg TID
2. Day 1-7: Continue flutamide alone (prevents flare from LHRH agonist)
3. Day 7: Initiate LHRH agonist (leuprolide 7.5 mg IM monthly OR depot formulation)
4. Continue both agents indefinitely

Alternative (Concurrent Start):

1. Day 1: Start both flutamide 250 mg TID AND LHRH agonist
2. Flare may occur but often clinically insignificant
3. Reserve this approach for lower disease burden

Integration with Prostate Cancer Treatment Protocols

NCCN-Aligned Protocol Considerations:

Modern Oncology Position: Flutamide is largely replaced by safer alternatives. Consider only when:

• Bicalutamide contraindicated or failed
• Cost is prohibitive barrier to bicalutamide
• Patient refuses alternatives after informed consent

Protocol for Antiandrogen Withdrawal

Antiandrogen Withdrawal Response (AAWR): When PSA rises on CAB, discontinuing flutamide may produce:

• PSA decline in 15-30% of patients
• Median response duration: 3-5 months
• Mechanism: Mutant AR that uses flutamide as agonist

Withdrawal Protocol:

1. Document PSA progression on CAB (2+ consecutive rises)
2. Discontinue flutamide
3. Continue LHRH agonist
4. Monitor PSA at 4, 8, and 12 weeks
5. If PSA declines > 50%, continue observation
6. If PSA rises, proceed to next-line therapy

Transitioning FROM Flutamide

To Bicalutamide:

1. Last dose of flutamide in evening
2. Start bicalutamide 50 mg next morning
3. No washout period needed
4. Continue LHRH agonist throughout

To Second-Generation Antiandrogen:

1. Discontinue flutamide
2. 1-2 week washout (allows AAWR assessment)
3. Initiate enzalutamide 160 mg daily OR apalutamide 240 mg daily OR darolutamide 600 mg BID
4. Continue LHRH agonist (or bilateral orchiectomy)

Protocol Integration Checklist

Before Initiating Flutamide:

• Confirmed metastatic or locally advanced prostate cancer
• Baseline LFTs within normal limits
• Reviewed medication list for hepatotoxic interactions
• Patient counseled on BLACK BOX warning
• Patient understands symptom reporting requirements
• Monthly LFT monitoring scheduled
• LHRH agonist prescribed (unless bilateral orchiectomy)
• Alternatives discussed (bicalutamide, other options)
• Patient accepts flutamide after informed consent

During Therapy:

• LFTs monthly x 4 minimum
• PSA monitoring per oncology protocol
• Symptom assessment at each visit
• Drug interaction review with any new medications
• Immediate access pathway if hepatotoxicity symptoms develop

Discontinuation Criteria:

• ALT or AST > 2x ULN
• Any elevation in bilirubin
• Jaundice, dark urine, or RUQ pain
• Disease progression (consider AAWR)
• Intolerable side effects
• Patient request after discussion

Document Completion: 2025-12-26 Status: PAPER 56 OF 76 COMPLETE - ENHANCED VERSION Next Paper: #57 - Finasteride